Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma Limited has submitted its financial results for the period ended December 31, 2025 to the stock exchange. This typically covers the company's Q3 FY26 (October–December 2025) standalone and/or consolidated performance. The actual revenue, profit, and margin figures are not included in the announcement text provided. Once the detailed results PDF is reviewed, key metrics like revenue growth, profit after tax (PAT), and EBITDA margins can be assessed. Investors should compare the numbers with street estimates and the previous quarter for trends. For now, this is only a submission notice without accompanying financial detail.
No immediate price impact can be assessed from this filing alone, as it is merely a regulatory submission intimation. Shareholders should wait for the full results document and the accompanying earnings call for actionable insights.